Stock listing
A2QD9S Stock Price, News, Filings & Events — Simcere Pharmaceutical Group Limited
Selected listing: A2QD9S · LS · EUR · DE
This page tracks Simcere Pharmaceutical Group Limited's A2QD9S:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2QD9S:LS. A2QD9S:LS is the stock-level entry point for investors researching Simcere Pharmaceutical Group Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A2QD9S:LS
- Asset type
- Stock
- Market cap
- $3.77B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Simcere Pharmaceutical Group Limited A2QD9S:LS stock context
This page tracks Simcere Pharmaceutical Group Limited's A2QD9S:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2QD9S:LS. A2QD9S:LS is the stock-level entry point for investors researching Simcere Pharmaceutical Group Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Simcere Pharmaceutical Group Limited
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
September 1, 2026
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
January 27, 2026
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
November 10, 2025
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
October 16, 2025
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refr...
June 18, 2025
Research Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited investor report
Review AI stock analysis and investor report context for A2QD9S:LS.
Simcere Pharmaceutical Group Limited company profile
View the public company page for Simcere Pharmaceutical Group Limited on 6ix.
Simcere Pharmaceutical Group Limited news
Read company news and market updates connected to Simcere Pharmaceutical Group Limited.
Simcere Pharmaceutical Group Limited investor events
Find investor webinars, events, and replay context for Simcere Pharmaceutical Group Limited.
Alternate listings
2096:HKEX
HK · HKD
Alternate listing for Simcere Pharmaceutical Group Limited; the primary context on this page is A2QD9S:LS.
SMHGF:OTC
US · USD
Alternate listing for Simcere Pharmaceutical Group Limited; the primary context on this page is A2QD9S:LS.
A2QD9S:LSX
DE · EUR
Alternate listing for Simcere Pharmaceutical Group Limited; the primary context on this page is A2QD9S:LS.
S2P:GETTEX
DE · EUR
Alternate listing for Simcere Pharmaceutical Group Limited; the primary context on this page is A2QD9S:LS.
S2P:TRADEGATE
DE · EUR
Alternate listing for Simcere Pharmaceutical Group Limited; the primary context on this page is A2QD9S:LS.
S2P:DUS
DE · EUR
Alternate listing for Simcere Pharmaceutical Group Limited; the primary context on this page is A2QD9S:LS.
S2P:FWB
DE · EUR
Alternate listing for Simcere Pharmaceutical Group Limited; the primary context on this page is A2QD9S:LS.
S2P:MUN
DE · EUR
Alternate listing for Simcere Pharmaceutical Group Limited; the primary context on this page is A2QD9S:LS.
S2P:SWB
DE · EUR
Alternate listing for Simcere Pharmaceutical Group Limited; the primary context on this page is A2QD9S:LS.